Biocon Share Price (BIOCON)
as on
| Source : NSE
🔔 Risk Alert
Biocon Biologics faces moderate-to-high risk if US pharmaceutical tariffs rise toward the 200% ceiling indicated by President Trump.
Biocon Stock Performance
as on August 26, 2025 at 4:01 pm IST
Day's Low
Day's High
₹355.6₹363.3
0.75%
Downside
1.40%
Upside
52 Week's Low
52 Week's High
₹291₹40618.78%
Downside
13.31%
Upside
| Market Stats | |
| Previous Close | ₹359.95 |
| Open | ₹358.95 |
| Volume | 42.16L |
| Upper Circuit | ₹395.90 |
| Lower Circuit | ₹323.95 |
| Day's Low | ₹355.6 |
| Day's High | ₹363.3 |
| 52 Week Low | ₹291 |
| 52 Week High | ₹406 |
| Returns % | |
| 1 Month Return | -7.52 % |
| 3 Month Return | + 6.94 % |
| 1 Year Return | + 1.57 % |
| 3 Year Return | + 18.06 % |
| 5 Year Return | -8.45 % |
Biocon Stock Fundamentals & Key Indicators
Check Biocon market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹47,903.41 Cr
Return on Equity (ROE)
0.4
PE Ratio (TTM)
111.27
Return on capital employed (ROCE)
2.07
Industry PE ratio
43.96
Beta (LTM)
1.16
P/B Ratio
3.55
Dividend Yield
0.15
PEG Ratio
-11.14
Quarterly Earnings Growth YOY
-89.65
EPS (TTM)
11.91
Sector
Pharmaceuticals
Book Value
180.27
Technical Analysis
Bearish
View Technical Analysis
Biocon Stock's Interest Amongst Investors
Biocon Stock Valuation
Track how Biocon P/E has moved over time to understand its valuation trends.
Biocon in the last 5 years
Lowest (24.48x)
March 19, 2024
Industry (43.96x)
August 26, 2025
Today (111.27x)
August 26, 2025
Highest (123.84x)
July 18, 2025
Today’s Price to Earnings Ratio: 111.27x
Biocon Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Biocon.
based on 20 analysts
57.89%
Buy
15.79%
Hold
26.32%
Sell
57.89% of analysts recommend a 'BUY' rating for Biocon. Average target price of ₹382.9
Source: S&P Global Market Intelligence
Biocon Share Price Target
Get share price movements and forecasts by analysts on Biocon.
Biocon price forecast by 20 analysts
Upside of6.87%
High
₹465
Target
₹382.90
Low
₹270
Biocon target price ₹382.9, a slight upside of 6.87% compared to current price of ₹358.3. According to 20 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Biocon revenue growth forecast
Expected growth rate Q1, FY2027:34.05%
Forecast
Actual
Including amortisation and stock based compensations
Biocon EPS growth forecast
EPS estimate Q1, FY2027:25.00%
Forecast
Actual
Source: S&P Global Market Intelligence
Biocon Ltd Financial Results
Get the annual and quarterly financial summary of Biocon Ltd, including revenue, profit, loss and more.
Biocon Earnings and Dividends
View detailed summary of the earnings and dividend history of Biocon.
Biocon Ltd Earnings Results
Biocon Ltd’s net profit fell -95.24% since last year same period to ₹31.40Cr in the Q1 2025-2026. On a quarterly growth basis, Biocon Ltd has generated -90.89% fall in its net profits since last 3-months.
Read More about Earnings ResultsBiocon Ltd Dividends May,2025
In the quarter ending March 2025, Biocon Ltd has declared dividend of ₹0.50 per share on 08 May 2025 - translating a dividend yield of 0.28%.
Read More about Dividends
Indices Featuring Biocon Stock
Check stock indices that include Biocon.
Biocon Stock Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Biocon.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.45% | ||
| Foreign Institutions | 6.04% | 6.60 | |
| Mutual Funds | 15.24% | 73.79 | |
| Retail Investors | 16.5% | ||
| Others | 7.77% | 8.36 |
Biocon Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Biocon with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 47,903.41 | -1.69% | 0.78 | 1,429 | 15,261 | |
| HOLD | 1,64,338.32 | 17.88% | 0.50 | 2,191 | 9,360 | |
| BUY | 1,21,997.33 | 32.49% | 0.66 | 1,911 | 11,516 | |
| HOLD | 31,756.80 | 1.19% | 0.53 | 698 | 5,616 | |
| BUY | 1,27,608.99 | 21.78% | 0.51 | 5,291 | 27,547 |
Biocon News & Key Events
Latest news and events in one place to help you make informed investing decisions in Biocon.
Biocon Receives FDA Approval for Diabetes Drug - 27 Aug, 2025
Biocon's unit, Biocon Pharma, has received tentative FDA approval for Sitagliptin tablets, enhancing its product portfolio amid profit pressures and mixed analyst ratings.Fitch Highlights Tariff Risks for Biocon's Revenue - 19 Aug, 2025
Fitch Ratings cautions that significant US tariffs on pharmaceutical exports could adversely affect Biocon Biologics, which derives 40% of its revenue from the US market.Biocon Reports Growth Amid Mixed Analyst Sentiment - 14 Aug, 2025
Biocon's Q1 FY26 earnings show revenue growth, particularly in biosimilars and GLP-1 drugs. However, ICICI Securities advises selling due to margin concerns.Biocon Faces Tariff Challenges Amid Growth Plans - 09 Aug, 2025
Biocon's acquisition of Viatris' biosimilars portfolio positions it for growth, contributing significantly to revenue. However, proposed US tariffs may impact profit margins and affordability.Biocon Reports Q1 Results: Profit Plummets Despite Revenue Growth - 07 Aug, 2025
Biocon announced a 95% drop in net profit for Q1 FY26, totaling ₹31 crore, while revenue rose 15% to ₹4,022 crore. The results missed market expectations, highlighting challenges despite growth in biosimilars and CRDMO segments.Biocon Faces Decline Amid New Product Plans - 05 Aug, 2025
Biocon Ltd is experiencing a decline, slipping for the fifth consecutive session, while also planning to launch generic versions of Wegovy in Canada within two years.Biocon Ltd Shows Stable Performance and Growth Potential - 30 Jul, 2025
Biocon Ltd's current price is ₹397.95, supported by stable biosimilar performance and strong growth from subsidiary Syngene. Despite risks in profitability and generics, the stock is trending positively with a target price of ₹454 in two to three months.
Insights on Biocon Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 8.77% to 15.24% in Jun 2025 quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 5.66% to 6.04% in Jun 2025 quarter
NO EFFECTAgainst Peers
In the last 1 year, Vimta Labs Ltd has given 126.2% return, outperforming this stock by 124.7%
- NO EFFECT
Against Peers
In the last 3 years, Vimta Labs Ltd has given 237.7% return, outperforming this stock by 219.6%
NEGATIVE IMPACTRevenue Fall
Revenue is down for the last 2 quarters, 4.47K Cr → 4.02K Cr (in ₹), with an average decrease of 10.1% per quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 344.5 Cr → 31.4 Cr (in ₹), with an average decrease of 90.9% per quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, BIOCON stock has moved down by -7.5%
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 60.64% to 54.45% in Jun 2025 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 17.76% to 16.50% in Jun 2025 quarter
About Biocon Ltd
Biocon's top products include insulin, monoclonal antibodies, enzymes, and vaccines. Its popular brands include Insugen, Insupen, and Insugen Plus. The company has a strong presence in the Indian market and is expanding its reach to other countries. Biocon has also established its presence in the US, Europe, and Japan.
Revenue: ₹3,910.10Cr as on June 2025 (Q1 FY26)
Net Profit: ₹89.20Cr as on June 2025 (Q1 FY26)
Listing date: 07 Apr, 2004
Chairperson Name: Kiran Mazumdar Shaw
| Organisation | Biocon Ltd |
| Headquarters | Bangalore |
| Industry | Pharmaceuticals |
| CEO | Kiran Mazumdar Shaw |
| E-voting on shares | Click here to vote |
Mutual Funds that own Biocon Stock
Check out the Mutual Funds with significant holdings in Biocon.
| Funds | Holdings | Prev. 5M |
|---|---|---|
| SBI Contra Fund Direct Growth | 2.39% | |
| SBI Midcap Fund Direct Growth | 2.43% | |
| Kotak Large & Midcap Direct Growth | 1.81% | |
| SBI Balanced Advantage Fund Direct Growth | 1.07% | |
| Nippon India Focused Fund - Direct Plan - Growth Option | 3.32% |
FAQs
What is Biocon share price today?
Biocon share price today stands at ₹358.3, Open: ₹358.95, Previous Close: ₹359.95, High: ₹363.3, Low: ₹355.6, 52 Week High: ₹406, 52 Week Low: ₹291 as on .
How to buy Biocon shares ?
To buy Biocon shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for BIOCON or Biocon Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Biocon shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is today's traded volume of Biocon?
Today's traded volume of Biocon is 42.16L. Which means that 42.16L shares of Biocon were bought and sold on the stock market during today's trading session.
What is Biocon's market cap today?
Today's market capitalisation of Biocon is ₹47,903.41 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Biocon?
Biocon’s 52 week high is ₹406 and 52 week low is ₹291. The current share price of Biocon is ₹358.3, which is -11.75% down from its 52 week high and 23.13% up from its 52 week low.